Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ropidoxuridine

An orally available 5-substituted 2-pyrimidinone-2'-deoxyribonucleoside analogue and prodrug of 5-iododeoxyuridine (IUdR), an iodinated analogue of deoxyuridine, with radiosensitizing activity. Upon oral administration, ropidoxuridine (IPdR) is efficiently converted to idoxuridine (IUdR) by a hepatic aldehyde oxidase. In turn, IUdR is incorporated into DNA during replication, thereby sensitizing cells to ionizing radiation by increasing DNA strand breaks. Compared to IUdR, ropidoxuridine is associated with a lower toxicity profile and improved anti-tumor activity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IPdR
Chemical structure:2(1H)-pyrimidinone, 1-(2-deoxy-beta-D-erythro-pentofuranosyl)-5-iodo-
5-iodo-2-pyrimidinone 2' deoxyribonucleoside
5-iodo-2-pyrimidinone-2'-deoxyribose
NSC code:726188
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search